Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10

Area of Science:

• Immunology
• Cancer Biology
• Cellular Signaling

Background:

• CD4(+)CD25(+) regulatory T cells are key immunosuppressive immune cells.
• Their role in inhibiting T lymphocyte effector functions during cancer progression is established.
• The impact of tumor-associated regulatory T cells on dendritic cell function remains largely unknown.

Purpose of the Study:

• To investigate the inhibitory effects of CD4(+)CD25(+) regulatory T cells from BCR-ABL(+) leukemia-bearing mice on dendritic cell function.
• To elucidate the molecular mechanisms underlying this regulatory T cell-mediated suppression of dendritic cells.

Main Methods:

• Isolation and co-culture of CD4(+)CD25(+) regulatory T cells from tumor-bearing mice with bone marrow-derived dendritic cells.
• Analysis of dendritic cell activation markers (CD80, CD86, CD40) and cytokine production (TNF-alpha, IL-12, CCL5/RANTES).
• Assessment of intracellular signaling pathways, including NF-kappaB activation, Smad signaling, and STAT3 activation, as well as the role of TGF-beta and IL-10.

Main Results:

• CD4(+)CD25(+)FoxP3(+) regulatory T cells from tumor-bearing mice significantly impaired dendritic cell function.
• Suppression was mediated by down-regulation of NF-kappaB activation in dendritic cells.
• Key co-stimulatory molecules and pro-inflammatory cytokines were reduced, with involvement of TGF-beta, IL-10, Smad, and STAT3 signaling.

Conclusions:

• Tumor-induced regulatory T cells actively suppress dendritic cell maturation and function.
• This suppression involves the inhibition of critical signaling pathways like NF-kappaB and relies on cytokines such as TGF-beta and IL-10.
• These findings highlight a novel mechanism of immune evasion in BCR-ABL(+) leukemia.